NanoViricides, Inc. (NYSE American: NNVC) announced that it will present at NIBA’s 152nd Investment Conference in Fort Lauderdale on March 12, where President and Executive Chairman Anil R. Diwan will outline progress on the company’s broad-spectrum antiviral platform. The company also reported that manufacturing of its NV-387 Oral Gummies drug product has been completed in preparation for patient dosing once clinical sites are ready, as the therapy advances toward a Phase II trial for monkeypox in the Democratic Republic of Congo following a successful Phase I safety study in healthy volunteers.
The completion of the oral gummy formulation marks a significant milestone for NanoViricides, as it provides a patient-friendly dosage form that could improve adherence in clinical trials and eventual commercial use. NV-387 is a broad-spectrum antiviral drug candidate that the company plans to develop for respiratory syncytial virus (RSV), COVID-19, long COVID, influenza, and other respiratory viral infections. Additionally, NV-387 has shown effectiveness in animal models for monkeypox (MPox), smallpox, and measles, positioning it as a potential therapeutic for multiple infectious diseases.
The upcoming presentation at the NIBA conference is expected to provide investors with insights into the company’s strategic direction and the timeline for the Phase II trial. The trial will be conducted in the Democratic Republic of Congo, where monkeypox is endemic, and follows a successful Phase I study that reported no adverse events in healthy volunteers. The company’s focus on advancing NV-387 into Phase II trials underscores its commitment to addressing unmet medical needs in antiviral therapy.
NanoViricides is a clinical-stage company specializing in creating special purpose nanomaterials for antiviral therapy. Its lead drug candidate, NV-387, represents a novel approach to treating viral infections by mimicking host cell receptors to neutralize viruses. The company’s pipeline also includes NV-HHV-1 for herpesvirus infections, though it cannot project an exact date for filing an Investigational New Drug (IND) application due to reliance on external collaborators and consultants.
For more information on NanoViricides and its latest updates, visit the company’s newsroom at https://ibn.fm/NNVC. The full press release is available at https://ibn.fm/AILOVA.
